Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.

Journal of the Chinese Medical Association : JCMA - 1 Apr 2025

Lai Jiun-I, Peng Yu-Ching, Chang Peter Mu-Hsin, Chang Yen-Hwa, Chung Hsiao-Jen, Huang Yi-Hsiu, Lin Tzu-Ping, Huang William J, Wei Tzu-Chun, Huang Tzu-Hao, Yen Chueh-Chuan

Abstract excerpt

BACKGROUND: Neuroendocrine prostate cancer (NEPC) (de novo or treatment-related [t-NEPC]) is a rare and deadly variant of prostate cancer. While de novo NEPC is rare, t-NEPC occurs more frequently in patients with castration-refractory prostate cancer. Owing to the rarity of NEPC, no standard treatment has been established, and the outcomes are generally unsatisfactory. METHODS: This study retrospectively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Neuroendocrine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Neoplasm Metastasis

Share to Prostatic Neoplasms

Share to Retinoblastoma Binding Proteins

Share to Treatment Outcome

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 40247437
DOI: 10.1097/JCMA.0000000000001209
PMCID: PMC12718932

Genes

DLL3
RB1

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.PMID 40247437Read ↗

Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.Semantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Treatment-related Neuroendocrine Prostate Carcinoma—Diagnostic and Molecular CorrelatesSemantic proximity Read ↗

[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].Semantic proximity Read ↗

Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factorsSemantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?Semantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving towards a Personalized Treatment?Semantic proximity Read ↗

The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerSemantic proximity Read ↗

Distinct prostate cancer neuroendocrine subtypes predict prognosis and guide personalized prostate-specific membrane antigen-targeted therapySemantic proximity Read ↗

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.Semantic proximity Read ↗

Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancerSemantic proximity Read ↗

Phase II trial of Pembrolizumab and Lenvatinib in Advanced Neuroendocrine Prostate Cancer (PLANE-PC)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.